ucsf banner
Helen Diller Family Compr Cancer Ctr
SARITA DUBEY, MD

Asst. Clinical Professor, Medicine, UCSF

CONTACT

(415) 353-9888 (appts)

Box 1705, UCSF; San Francisco, CA 94143-1705

additional websites:

UCSF Physician Referral Directory

EDUCATION

Kilpauk Medical College, Chennai, India MBBS, 1994, Medicine
Hennepin County Medical Center, Minneapolis, MN, MD, 2001, Internal medicine
University of Wisconsin, Madison, WI, MD, 2003, Medical Oncology

PROFESSIONAL EXPERIENCE

1998-2001

Internal Medicine Residency, Hennepin County Medical Center, Minneapolis, MN

2001-2003

Medical Oncology Fellowship, University of Wisconsin, Madison, WI

2003- 2005

Clinical Instructor, Academic Medical Oncologist Training Program, University of Wisconsin, Madison, WI

HONORS & AWARDS

1989

Distinctions in Anatomy, Kilpauk Medical College, Chennai, India

1991

Distinctions in ENT, Kilpauk Medical College, Chennai, India

1999

Journal Club Award, Hennepin County Medical Center, Minneapolis, MN

2003

ECOG Travel Award, Young Investigator Symposium

2004

Women Against Lung Cancer travel award for the Annual Meeting of the American Society of Clinical Oncology

2005

Women Against Lung Cancer International travel award for the 11th World Conference on Lung Cancer

PUBLICATIONS

Sherry Morgan-Meadows, Sarita Dubey, Michael Gould, et al. Phase I Trial of Perillyl Alcohol Administered Four Times Daily Continuously. Cancer Chemotherapy and Pharmacology, 2003; 52: 361-366.

Sarita Dubey, Joan H Schiller. Chemotherapy for Advanced Non-Small Cell Lung Cancer. Hematology and Oncology Clinics of North America, 2004; 18: 101-114.

Sarita Dubey, Joan H Schiller. Management strategies for small cell lung cancer. Oncology Special Edition, 2004; 7: 131-134

Sarita Dubey, Roger L. Brown, Sarah L. Esmond, Barbara J. Bowers, Janet M. Healy, Joan H. Schiller. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. Journal of Supportive Oncology, 2005; 3: 149-154.

Sarita Dubey, Joan H Schiller. New drugs for NSCLC; Pemetrexed, Bortezomib, and Cetuximab. The Oncologist 2005; 10: 282-91

4/28/06

This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device. Please upgrade your browser.